1. Home
  2. Labeler Index
  3. Astrazeneca Pharmaceuticals Lp
  4. 0310-1349
  5. Product Images: Tagrisso

Product Images Tagrisso

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tagrisso NDC 0310-1349 by Astrazeneca Pharmaceuticals Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Tagrisso 40 mg tablet bottle label

Tagrisso 40 mg tablet bottle label

isso® griss Ta (osimertinib) tablets - NDG 0310-1349-30 30 Tablets - Rx only - Manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 by AstraZeneca AB, SE-151 85 Sodartaf, Sweden - Product of Switzerland - GTIN 00303101349307.*

Tagrisso 80 mg tablet bottle label

Tagrisso 80 mg tablet bottle label

The text describes a medicine named Tagrisso, which comes in tablets of 80mg each, with a package of 30 tablets. It provides the NDC code (0310-1350-30), the manufacturer (AstraZeneca AB, based in Sweden) and the product's country of origin (Switzerland). The medicine is prescription-only (Rx only).*

chem_structure - chemical structure

chem_structure - chemical structure

figure 1 adaura

figure 1 adaura

figure 2

figure 2

This text provides data on the probability of progression-free survival for two different treatments (TAGRISSO and EGFRTKI) at various time points (0, 3, 6, 9, 12, 15, 18, 21, 24, 27 months) after randomization. The numbers in the table represent the percentage of patients who had progression-free survival with each treatment at each time point. The symbol "+" indicates censored patients.*

figure 3

figure 3

This appears to be survival analysis data represented in a table format. The table shows the probability of overall survival for patients taking either TAGRISSO or EGFRTKI. The time from randomization (in months) is plotted on the x-axis and the number of patients is plotted on the y-axis. The table also shows the number of patients at risk for each medication at each time interval.*

figure 4

figure 4

This is a graph showing the Probability of Progression-free survival for two treatments, TAGRISSO and Chemotherapy, over the course of 18 months. The X-axis shows the time since randomization in months. The Y-axis represents the Probability of Progression-free survival. The graph shows that TAGRISSO has a higher Probability of Progression-free survival than Chemotherapy throughout the 18 months. The numbers at the base of the figure indicate the number of subjects at risk for each treatment group.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.